Valerie E. Polcz

Valerie E. Polcz

Auto-generated profile, based on publicly available information

Valerie E. Polcz

Sepsis and Critical Illness Research Center, Department of Surgery, University of Florida College of Medicine, Gainesville, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
PEPhilip A. Efron
Philip A. Efron
SBScott Brakenridge
Scott Brakenridge
AMAlicia Mohr
Alicia Mohr
EBEvan L. Barrios
Evan L. Barrios
VPValerie E. Polcz
Valerie E. Polcz
FMFrederick A. Moore
Frederick A. Moore
Export

23 January 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
EBEvan L. Barrios
Evan L. Barrios
MMMonty Mazer
Monty Mazer
PMPatrick W. McGonagill
Patrick W. McGonagill
CBChristian B. Bergmann
Christian B. Bergmann
MGMichael D. Goodman
Michael D. Goodman
CCCharles Caldwell
Charles Caldwell
BACKGROUND: Sepsis remains a major clinical challenge for which successful treatment requires greater precision in identifying patients at increased risk of adverse outcomes requiring different therapeutic approaches. Predicting clinical outcomes and immunological endotyping of septic patients generally relies on using blood protein or mRNA biomarkers, or static cell phenotyping. Here, we sought to determine whether functional immune responsiveness would yield improved precision. METHODS: An ex vivo whole-blood enzyme-linked immunosorbent spot (ELISpot) assay for cellular production of interferon γ (IFN-γ) was evaluated in 107 septic and 68 nonseptic patients from 5 academic health centers using blood samples collected on days 1, 4, and 7 following ICU admission. RESULTS: Compared with 46 healthy participants, unstimulated and stimulated whole-blood IFN-γ expression was either increased or unchanged, respectively, in septic and nonseptic ICU patients. However, in septic patients who did not survive 180 days, stimulated whole-blood IFN-γ expression was significantly reduced on ICU days 1, 4, and 7 (all P < 0.05), due to both significant reductions in total number of IFN-γ–producing cells and amount of IFN-γ produced per cell (all P < 0.05). Importantly, IFN-γ total expression on days 1 and 4 after admission could discriminate 180-day mortality better than absolute lymphocyte count (ALC), IL-6, and procalcitonin. Septic patients with low IFN-γ expression were older and had lower ALCs and higher soluble PD-L1 and IL-10 concentrations, consistent with an immunosuppressed endotype. CONCLUSIONS: A whole-blood IFN-γ ELISpot assay can both identify septic patients at increased risk of late mortality and identify immunosuppressed septic patients. TRIAL REGISTRY: N/A. FUNDING: This prospective, observational, multicenter clinical study was directly supported by National Institute of General Medical Sciences grant R01 GM-139046, including a supplement (R01 GM-139046-03S1) from 2022 to 2024.

16 May 2023 in Surgery
Verified
Journal Article
Closed access
EBEvan L. Barrios
Evan L. Barrios
VPValerie E. Polcz
Valerie E. Polcz
SHSara E. Hensley
Sara E. Hensley
GSGeorge A. Sarosi
George A. Sarosi
AMAlicia M. Mohr
Alicia M. Mohr
NGNicole Gravina
Nicole Gravina

19 June 2024 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
VPValerie E. Polcz
Valerie E. Polcz
EBEvan L. Barrios
Evan L. Barrios
SLShawn D. Larson
Shawn D. Larson
PEPhilip A. Efron
Philip A. Efron
JRJaimar C. Rincon
Jaimar C. Rincon

2 June 2023 in Annals of Surgery
Verified
Journal Article
Open access
BNBindi Naik-Mathuria
Bindi Naik-Mathuria
AUAlan F Utria
Alan F Utria
PEPeter F. Ehrlich
Peter F. Ehrlich
JAJennifer H. Aldrink
Jennifer H. Aldrink
AMAndrew Murphy
Andrew Murphy
DRDavid H. Rothstein
David H. Rothstein
Objective: The purpose of this study was to describe management and outcomes from a contemporary cohort of children with Wilms tumor complicated by inferior vena caval thrombus. Background: The largest series of these patients was published almost 2 decades ago. Since then, neoadjuvant chemotherapy has been commonly used to manage these patients, and outcomes have not been reported. Methods: Retrospective review of 19 North American centers between 2009 and 2019. Patient and disease characteristics, management, and outcomes were investigated and analyzed. Results: Of 124 patients, 81% had favorable histology (FH), and 52% were stage IV. IVC thrombus level was infrahepatic in 53 (43%), intrahepatic in 32 (26%), suprahepatic in 14 (11%), and cardiac in 24 (19%). Neoadjuvant chemotherapy using a 3-drug regimen was administered in 82% and postresection radiation in 90%. Thrombus level regression was 45% overall, with suprahepatic level showing the best response (62%). Cardiopulmonary bypass (CPB) was potentially avoided in 67%. The perioperative complication rate was significantly lower after neoadjuvant chemotherapy [(25%) vs upfront surgery (55%); P=0.005]. CPB was not associated with higher complications [CPB (50%) vs no CPB (27%); P=0.08]. Two-year event-free survival was 93% and overall survival was 96%, higher in FH cases (FH 98% vs unfavorable histology/anaplastic 82%; P=0.73). Neither incomplete resection nor viable thrombus cells affected event-free survival or overall survival. Conclusions: Multimodal therapy resulted in excellent outcomes, even with advanced-stage disease and cardiac extension. Neoadjuvant chemotherapy decreased the need for CPB to facilitate resection. Complete thrombectomy may not always be necessary.

3 November 2022 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
ARAudra J. Reiter
Audra J. Reiter
MIMartha-Conley E. Ingram
Martha-Conley E. Ingram
MRMehul V. Raval
Mehul V. Raval
EGElisa Garcia
Elisa Garcia
MHMadelyn Hill
Madelyn Hill
LBLoren Berman
Loren Berman